FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Expires: November 30, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

CUBIST PHARMACEUTICALS INC

2. Date of Event Requiring Statement (MM/DD/YYYY)
12/7/2011 

3. Issuer Name and Ticker or Trading Symbol

ADOLOR CORP [ADLR]

(Last)        (First)        (Middle)

65 HAYDEN AVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

LEXINGTON, MA 02421       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value $0.0001 per share   36090910   I   See footnote   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  The reported shares are owned directly by FRD Acquisition Corporation, a wholly-owned subsidiary of Cubist Pharmaceuticals, Inc. Cubist Pharmaceuticals, Inc. is an indirect beneficial owner of the reported shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
CUBIST PHARMACEUTICALS INC
65 HAYDEN AVE
LEXINGTON, MA 02421
X

FRD Acquisition Corp
65 HAYDEN AVE
LEXINGTON, MA 02421
X


Signatures
CUBIST PHARMACEUTICALS, INC. FRD ACQUISITION CORPORATION By: /s/ Tamara L. Joseph, Senior Vice President, General Counsel and Secretary of Cubist and Secretary of FRD Acquisition Corporation 12/9/2011
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Adolor Corp. (MM) Charts.
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Adolor Corp. (MM) Charts.